"Vesicle targeting, rough ER to cis-Golgi"

Across TCGA pan-cancer cohorts, RNA activity of the "Vesicle targeting, rough ER to cis-Golgi" pathway differs between tumor and matched normal tissue in 13 of the 18 cancer types tested.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as KIRP and THCA, show the opposite pattern, with lower activity in tumor tissue.

KIRP, THCA, and COAD show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
KIRP	Male	III,IV	−0.042	<.001	11	view →
THCA	All	II,III,IV	−0.036	<.001	11	view →
COAD	Male	II,III,IV	−0.045	<.001	9	view →
HNSC	Male	II,III,IV	−0.034	<.001	5	view →
KICH	Male	All	−0.028	.001	5	view →
CHOL	All	All	+0.052	.001	2	view →
READ	All	All	−0.051	.003	2	view →
UCEC	All	II,III,IV	−0.031	.034	2	view →
LIHC	Female	II,III,IV	+0.026	.003	2	view →
ESCA	Female	All	−0.080	.001	1	view →
STAD	Male	II,III,IV	−0.030	.045	1	view →
LUSC	Male	II,III,IV	−0.024	.030	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 13 lineages.

GO:0048207–KIRP

Open the KIRP breakdown →